These compounds may interact with:
G1/S-specific cyclin-D1
Potentially involved in: cancer; multiple myeloma; immune system cancer; lymphoid leukemia; endometrial cancer; breast cancer; kidney cancer; carcinoma; adenoma; ductal carcinoma in situ; gastrointestinal system disease; vascular disease; parathyroid adenoma; intestinal benign neoplasm; familial adenomatous polyposis; primary hyperparathyroidism; papilloma; adenocarcinoma; anemia; anorexia
Disease data sourced from Pharos.